Abstract | Consensus practice guidelines and the implementation of clinical therapeutic advances are usually based on the results of large, randomized clinical trials (RCTs). However, RCTs generally inform us on an average treatment effect for a presumably homogeneous population, but therapeutic interventions rarely benefit the entire population targeted. Indeed, multiple RCTs have demonstrated that interindividual variability exists both in drug response and in the development of adverse effects. The field of pharmacogenomics promises to deliver the right drug to the right patient. Substantial progress has been made in this field, with advances in technology, statistical and computational methods, and the use of cell and animal model systems. However, clinical implementation of pharmacogenetic principles has been difficult because RCTs demonstrating benefit are lacking. For patients, the potential benefits of performing such trials include the individualization of therapy to maximize efficacy and minimize adverse effects. These trials would also enable investigators to reduce sample size and hence contain costs for trial sponsors. Multiple ethical, legal, and practical issues need to be considered for the conduct of genotype-based RCTs. Whether pre-emptive genotyping embedded in electronic health records will preclude the need for performing genotype-based RCTs remains to be seen.
Introduction
The aim of individualized medicine is to deliver the right drug to the right patient. Pharmacogenomics is a critical component of individualized medicine, and is the study of the role of inheritance in individual vari ation in drug response. 1, 2 The clinical goals of pharmaco genomics are to maximize drug efficacy, avoid adverse drug effects, and target responsive patients. The research goals are to enhance our understanding of disease by discovery of new pathways and mechanisms of action. The field has evolved considerably with advances in DNA genotyping and sequencing technology, new bioinformatics tools and statistical methodology, use of electronic health records and biobanks, and func tional validation of genetic signals using in vitro cell systems and animal models. [4] [5] [6] [7] [8] [9] Clinical implementa tion of pharmaco genomics is, however, still nascent, especially in cardio vascular disease. 3 The FDA have included details of 119 drug-gene pair associations in drug labelling; however, the information relating to only 15% of these associ ations is based on convincing ran domized clinical trial (RCT) data. 10 Of the small number of cardio vascular drug-gene pairs described in drug labels, two had adequate or convincing clinical valid ity, but none had convincing clinical utility. Interest in using biomarkers to stratify or target patients in cardio vascular RCTs is increasing, 11 but genotypebased RCTs have been initiated only over the past 6 years. [12] [13] [14] Using genotype as a biomarker of drug response or toxicity in RCTs enables the use of smaller sample sizes, a decrease in costs, an increase in the l ikelihood of success, and the m inimization of adverse events.
In this Review, we provide an overview of the efforts to implement pharmacogenomics into clinical prac tice using the goldstandard approach of RCTs. We first discuss the current approaches used to identify pharmaco genetic markers, the evidence supporting their clinical validity, and the rationale for their use in RCTs. We then describe the various RCT designs in which pharmaco genetic markers could be used, with specific examples of c ardiovascular studies related to drug-gene pairs.
Identifying pharmacogenetic markers
Genetic variation that is associated with a particular drugresponse phenotype is considered a pharmaco genetic marker. Studies linking genotype with drug response phenotype are performed to identify relevant pharmacogenetic markers that can subsequently be used in clinical practice ( Figure 1 ). Pharmacogenetic markers can be used to identify individuals who do or do not respond to drugs, as well as individuals who are at risk of drug toxicity.
sequencing technology, extreme drugresponse pheno types-defined typically as those individuals with drug response ≤5 th percentile, or ≥95 th percentile-are more commonly used to identify novel pharmacogenetic markers (for example, in warfarin dosing). 18 The concept of pharmacogenetics has also been extended to functional genetic variation in potential drug targets that supports the use of a drug in a certain disease process (for example, variation in Niemann-Pick C1like protein 1 and use of ezetimibe in patients with coronary artery disease 19 ). The identification of mutations in potential drug targets has enabled the development of novel drugs for various types of cancer previously con sidered untreatable (for example, vemurafenib, a BRAF kinase inhibitor for metastatic melanoma that is positive for a BRAF V600E mutation 20 ) .
Genotyping or sequencing studies
The three broad research strategies that have been adopted to identify pharmacogenetic markers are candidate gene studies, genomewide association studies (GWAS), and nextgeneration sequencing approaches ( Figure 1 ).
Candidate gene studies
An altered drugresponse phenotype can result from genetic variation in the known pharmacokinetic or pharmacodynamic pathway of a drug. The pharmaco kinetic pathway consists of factors that influence the drug's absorption, distribution, metabolism, or excre tion, thereby influencing the concentration of the drug that reaches the target. The pharmacodynamic pathway consists of the drug's target itself and/or signalling path ways downstream that mediate drug effect. Therefore, candidate gene studies involve DNA genotyping or sequencing of individuals for common or rare variation in genes that comprise the known pharmaco kinetic and/ or pharmacodynamic pathways of the drug. A genetic association study is then performed to identify the pharmacogenetic marker that is significantly associ ated with the drug pheno type. Candidate gene studies have resulted in successful identification of various pharmaco genetic markers, including CYP2C19 for clopidogrel use (pharmaco kinetic pathway), CYP2C9 for warfarin use (pharmaco kinetic pathway), 21 
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Key points ■ Substantial progress has been made in the field of pharmacogenomics, with advances in genotyping and sequencing technology, and by the routine collection of DNA samples to study the drug-response phenotype ■ Genetic markers associated with drug toxicity and drug efficacy can be identified by candidate gene, genome-wide association, and next-generation sequencing studies ■ The potential of targeting the right patient with the right drug, and FDA labelling guidance to use pharmacogenetic markers, have provided new impetus to conduct genotype-based randomized clinical trials (RCTs) ■ Prospective approaches using a pharmacogenetic-based strategy with enrichment or adaptive designs are being increasingly used in cardiovascular RCTs ■ Clinical adoption of pharmacogenetics in the practice of cardiovascular medicine will become a reality when a transition has been made from conducting genetic association studies to rigorously performed genotype-based RCTs for warfarin use (pharmacodynamic pathway), 22 and ADRB1 for buncindolol use (pharmacodynamic pathway). 16 The disadvantage of candidate gene studies, however, is their inability to identify genetic variants in asyetundiscovered p athways that might i nfluence the drugresponse phenotype.
GWAS
Millions of single nucleotide polymorphisms (SNPs) across the entire genome are assayed in GWAS, and these studies, therefore, have the potential to identify variants in genes that might not have been previously considered to influence the drugresponse phenotype. An example of the success of this approach for drug toxicity is the identification of the noncoding SNP rs4363657 in the SLCO1B1 gene on chromosome 12, which was iden tified as being significantly associated with statin myo pathy (P = 2.0 × 10 -9 ; OR 16.9 for CC homozygotes and 4.5 for CT heterozygotes).
17 SLCO1B1 encodes OATP1B1, a solute carrier organic transporter responsible for the active transport of statins into hepatocytes and, therefore, plasma clearance and subsequent metabolism of the drug.
In addition to the identification of genetic variants not previously considered to potentially influence drug response, GWAS have also been used to confirm the role of candidate genes thought to influence drugresponse phenotypes. The first GWAS performed to assess vari ability in warfarin dosing to achieve therapeutic anti coagulation confirmed the role of SNPs in the warfarin drug target VKORC1 (rs9923231, P = 5.4 × 10 -78 ) and the cytochrome P450 metabolizing enzyme CYP2C9 (rs1057910, P = 4.5 × 10 -17 ; rs1799853, P = 8.8 × 10 -13 ). 15 Moreover, the association between the CYP4F2 gene and warfarin metabolism was previously controversial; 23 however, after adjusting for age, sex, and the known genes that influence warfarin dosing (VKORC1 and CYP2C9), the single coding SNP rs2108622 in the CYP4F2 gene was found to have genomewide s ignificance (P = 8.3 × 10 -10 ). 15 The limitations of GWAS are the inability to identify variants with small effect size, especially when associ ated with a drugresponse phenotype that is not directly related to drug effect. For example, compared with variability in clopidogrel inhibition of platelet aggre gation, a GWAS assessing death as the end point is less likely to result in identification of a CYP2C19 variant that is of genomewide significance. Genetic variants with small effect size require large sample sizes and replication of findings is essential to infer significant and clinically valid associations between the geno type and the drugresponse phenotype. Finding an appropriately powered replication study to assess such associations can be extremely challenging. 24, 25 GWAS identify common genetic variants and, therefore, can miss rare variants with potentially large effect size that might account for the missing heritability of complex drugresponse phenotypes. 26 Next-generation sequencing Nextgeneration sequencing technology is increas ingly being used in the field of pharmacogenomics to identify rare genetic variants that are associated with drug response. 18, 27 In response to decreasing costs of sequencing, whole genome and whole exome sequen cing studies are being used to identify clinically relevant, rare genetic variants. 28 Whole exome sequencing has identified rare coding variants in KCNE1 (a potassium channel gene) and ACN9 (a gluconeogenesis pathway gene) as being risk factors for druginduced long QT syndrome. 27 Individuals at risk were also found to have an increased prevalence of rare variants that have been implicated in congenital long QT syndrome. 27 Whole exome sequencing has also been performed to identify genetic variants that contribute to extreme warfarin dose variability (≤35 mg per week or ≥49 mg per week) in AfricanAmerican individuals. 18 For the first time, an association between genetic variation in the folate home ostasis pathway (rs7856096 in the folate homeostasis gene FPGS) and warfarin dose variability (in this case, lower warfarin doses) was demonstrated in AfricanAmerican individuals (P = 1.8 × 10 -8 ).
Despite being a new technology with the capacity to identify rare culprit variants, nextgeneration sequencing is not a panacea for identifying all inheritance patterns in pharmacogenomics. Copy number and long insertiondeletion variants are examples of genetic variant types that are not reliably detected by whole exome or whole genome sequencing. 29 Additionally, ordering clinicians might not have the necessary expertise to interpret inci dental genetic results that are highly medically action able. 30 The increased sensitivity of nextgeneration sequencing in detecting multiple rare and common genetic variants of uncertain functional relevance, and the small sample sizes used in these type of studies, make the interpretation of these associations with drugresponse phenotypes challenging. 31 
Rationale for genotype-based RCTs
The implementation of pharmacogenetics in clinical practice faces many challenges, including the availability of genotyping or sequencing that can be performed in a Clinical Laboratory Improvements Amendments (CLIA) approved laboratory in a timely manner, userfriendly decision support tools and, perhaps most importantly, the lack of demonstration of clinical utility in well designed RCTs. 3, 10 The rationale for performing such genotypebased RCTs is outlined below. Variable drug response and toxicity The role of inheritance in variable drug response has been anecdotally observed for many years. 32 A 20fold variation between individuals is observed in those trying to achieve therapeutic anticoagulation using warfarin, with genetic factors contributing up to 30% of this dose variability. 1, 18, 33 Genetic factors also have a role in the pharmacokinetics of newer anticoagulants such as dabigatran; the presence of each CES1 rs2244613 minor allele resulted in a 15% decrease in dabigatran trough levels and a lower risk of bleeding with the drug. 34 The widely used antiplatelet drug clopidogrel is converted to an active metabolite by the cytochrome P450 enzyme CYP2C19, a protein that is encoded by a highly poly morphic gene. Variation in CYP2C19 has been associated with significantly reduced active clopidogrel metabolite levels, high residual platelet reactivity, and an increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention (PCI). 35, 36 However, genetic variation that could alter drug pharmacokinetics or pharmacodynamics is not always associ ated with a predictable drug response. An example is azathioprine, an important immunosuppressant drug used in heart transplantation. Azathioprine is metabo lized by thiopurine Smethyltransferase (TPMT). Loss offunction genetic variation in TPMT could result in higher levels of active azathioprine metabolite, and c arriers could be at an increased risk of lifethreatening leucopenia when treated with azathioprine. 37, 38 Heart transplantation recipients who are carriers of lossof function TPMT genetic variants with higher azathioprine levels should, theoretically, also have a lower likelihood of cardiac rejection. Conversely, in vitro lymphocyte proliferation assays and assessment of cardiac rejec tion by endomyocardial biopsy in patients with inac tive TPMT alleles have suggested that, compared with wildtype patients, azathioprine use in these individuals might result in a higher risk of rejection. 39, 40 Therefore, although studies might demonstrate convincing associ ations between genotype and drugresponse phenotype, rigorously conducted RCTs are needed before we start considering these drug-gene pairs in clinical practicealtering therapy on the basis of these associations might not always result in the desired outcomes, as seen in trials based on platelet function testing. 41, 42 Success in other medical specialties A few pivotal genotypebased RCTs have resulted in change to clinical practice. The drug-gene pair abacavir-HLA-B*5701 was successfully assessed in an RCT and is a good example of how pharmacogenetic markers can be used to prevent toxicity and thereby improve outcomes. Abacavir is a nucleoside reversetranscriptase inhibitor that is used to treat patients with HIV, but can result in a potentially fatal hypersensitivity reaction in 5-8% of patients taking the drug. [43] [44] [45] [46] [47] The association between HLA-B*5701 and abacavirinduced hypersensitivity reac tion was demonstrated and replicated in multiple gene association studies. [43] [44] [45] [46] [47] Approximately 6 years after the initial report, patients with HIV were randomly assigned to prospective HLA-B*5701 screening before abacavir treatment (n = 980) or to the control group (n = 976) in a doubleblind, prospective study. 48 Immunologically con firmed hypersensitivity reactions occurred in none of the patients in the prospective genetic screening group versus 2.7% of those in the control group (P <0.001), thus dem onstrating the utility of a pharmacogenetic test in redu cing the incidence of drug toxicity. 48 The trial findings led to the use of HLA-B*5701 screening before abacavir use in the clinical setting. The large effect size (approxi mately 50% of HLA-B*5701 carriers develop hypersensi tivity when exposed to abacavir) and the relatively high prevalence of the associated minor allele contributed to the successful outcome of this trial. 48 The G551D mutation in the cystic fibrosis transmem brane conductance regulator gene (CFTR) is an example of a pharmacogenetic marker that can be successfully used to improve treatment outcomes. An RCT demon strated the benefit of ivacaftor therapy in 161 patients with cystic fibrosis who were carriers of the G551D mutation. 49 The success of this trial highlights the pos sibility of using a small sample size if the RCT is enriched with potential responders who are genetically identified.
FDA labelling
The FDA has provided pharmacogenetic information in drug labels for a small number of cardiovascular drugsmetoprolol, carvedilol, propranolol, propafenone, statins, isosorbide, hydralazine, clopidogrel, and warfarin-in an attempt to guide physicians who prescribe these drugs. 50 The pharmacogenetic information provided for meto prolol, carvedilol, propranolol, and propafenone are pri marily based on the effect of CYP2D6 metabolizer status on the pharmacokinetics of the drug. The only cardio vascular drugs that have specific pharmaco genetic drug label recommendations are warfarin (relating to dose adjustments) and clopidogrel (for the use of alternative antiplatelet drug therapy in poor metabolizers). Groups such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) have provided prescribing guide lines for these drugs on the basis of findings reported in the available literature as well as FDA recommenda tions. 33, 51 Clinical validity (defined as the capacity to predict drug response) and clinical utility (defined as improvement of clinical outcomes) have been examined for various drug-gene pairs identified in drug labels. 10 The warfarin-CYP2C9/VKORC1 and clopidogrel-CYP2C19 drug-gene pairs demonstrated clinical validity, but did not fulfil criteria for clinical utility. 10 "A system atic review or metaanalysis of RCTs showing consist ency in results or at least one large RCT" 10 was required for the demonstration of clinical utility, highlighting the importance of performing RCTs for the clinical implementation of pharmacogenetics.
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Point-of-care genotyping A short turnaround time is often important for geno typebased therapeutic interventions to be implemented in clinical trials and clinical practice. The availability of pointofcare genotyping has overcome the limitations of a time delay caused by traditional genotyping, and allows genotypeguided therapy to be initiated in a timely manner. An example, which has been effectively utilized in a genotypebased clinical trial, 53 is the FDAapproved pointofcare Spartan RX™ CYP2C19 genotyping plat form (Spartan Biosciences, Canada) that uses a buccal swab to provide results of a patient's CYP2C19*2 and *3 carrier status within 1 h. The importance of providing genotyping results in a timely manner was also seen in the warfarin pharmacogenetic trials. In EUPACT, 12 a pointofcare genetic test provided results within 2 h to guide warfarin dosing for all patients randomly assigned to the genotyping group. However, in COAG, 13 genetic results were available for only 45% of individuals on the first day after randomization, resulting in the use of a clinical algorithm without the genotype data in the genotypeguided dosing strategy group.
Pharmacoeconomic considerations
The administration of the right drug to the right patient could reduce healthcare costs by enhancing drug effi cacy and reducing drug toxicity, and thereby resulting in reduced hospital admissions and utilization of health care services. Generic clopidogrel is approximately one sixth of the cost of the newer antiplatelet drugs, and a strategy of using this therapy in wildtype CYP2C19 patients could result in considerable cost savings com pared with the universal use of newer antiplatelet drugs. Indeed, costeffectiveness analyses have demonstrated that substantial cost savings could be achieved with a genotypebased strategy compared with empirical use of the newer P2Y 12 inhibitors for all patients after PCI to overcome 'genetic clopidogrel resistance' . 54, 55 According to one study, compared with prasugrel use in all patients, the use of prasugrel and clopidogrel in a genotypeguided strategy resulted in an incremental costeffectiveness ratio of US$30,200 per qualityadjusted life year. 55 The major limitation of these studies is that cost assumptions are based on outcomes from post hoc analyses of RCTs. The true value of a genotypebased approach can be determined only from prospective genotypebased RCTs.
Phase II trial pharmacogenomics Performing GWAS and whole exome or whole genome sequencing in a small phase II trial might enable early identification of common or rare variants associated with drug response or toxicity that have a large effect size. 56 Such an approach might then allow enrichment of phase II trials with responders and/or exclusion of patients at risk of adverse events. The benefits of such an approach would be a smaller sample size, lower costs of performing such a trial, and greater likelihood of a positive result.
Genomic clinical trial design
Over the past several decades, phase III RCTs have often required multiple thousands of patients to dem onstrate clinically meaningful, but modest, benefits in an unselected patient population. In the past decade, however, some investigators have proposed RCT protocols that attempt more accurately and selectively to identify patients who might benefit from treatment. In many cases, especially in the field of oncology, these RCT protocols are now in use. The refined RCT designs fall into two general categories-retrospective and prospec tive design. Prospective designs can be further divided into various possible approaches. The examples cited below are primarily from the oncology field, but could be applied to cardiovascular disease.
Retrospective approach
Retrospective study designs aim rigorously and formally to identify a potential predictive marker from an already completed RCT. This approach is desirable when an RCT has already been completed (at least through the enrol ment period) and a potential pharmacogenetic marker is identified from a source outside of the RCT. In this circumstance, if banked specimens are available from the completed RCT, a prospectively defined analysis plan can be developed to test whether the treatment effect differs by the level of a pharmacogenetic marker. To be able to address the pharmacogenetic marker hypoth esis, this 'prospective-retrospective' strategy requires biospecimens to be available from a large proportion of all patients enrolled in the RCT (to prevent selection bias) and not to have been used in the development of the assay under investigation. A prospective analysis plan completed before any pharmacogenetic marker analyses, and sufficient statistical power with the existing sample size of the RCT, are also necessary. 57 Moreover, to be considered 'definitive' , the entire validation process should be duplicated on a second patient cohort from an independent trial. This independent validation is crucial because, although prespecification adds substantial cred ibility to the initial validation, multiple markers could be tested from a single trial, which increases the risk of a falsepositive finding.
This approach has been successfully used to establish the predictive capacity of RAS mutations as a marker for lack of benefit of inhibitors of the epidermal growth factor receptor in patients with colorectal cancer. 58 Retrospective DNA analysis has been performed in two RCTs demonstrating the superiority of alternative anti platelet therapy to clopidogrel in reducing major adverse cardiovascular events in carriers of the CYP2C19 loss offunction allele, but the stringent criteria described above were not met in these genetic substudies. 59, 60 For example, DNA analysis was performed in only 21% of the TRITON38 trial 60 participants and 55% of the PLATO study 59 population, none of these genetic substudies was prospectively powered to address the hypothesis definitively, and no duplicate trials have been available to va lidate these findings.
Prospective approach
Prospective validation remains the gold standard for any therapeutic approach, including biomarkerbased treatment. Multiple prospective strategies have been developed (Figure 2 ) to test for treatment efficacy in the context of a biomarker.
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Enrichment designs
The most statistically straightforward prospective approach is the enrichment design (Figure 2a) , in which only patients who have the feature thought to predict clinical benefit (that is, a specific mutation, blood type, or disease characteristic) are included in the RCT. Examples of cardiovascular genotypebased RCTs that have an enrichment design are TAILORPCI 61 and GENETICAF.
62 If the marker used to select patients is truly predictive of differential benefit, this approach can substantially reduce the required sample size compared with the unselected design, which would also include the cohort of patients with little or no likelihood of benefit. 63 This approach, however, leaves multiple questions un answered: does the treatment have benefit in excluded patients, could the biomarker used to select patients be further optimized and, if the trial produces negative findings, are they a result of a failure of the biomarker or of the treatment itself? Nevertheless, when justified by appropriate preliminary data, the use of enrichment designs offers the potential for smaller, moreefficient trials and, equally importantly, the avoidance of treating patients who have little or no likelihood of benefiting from the therapy.
In the absence of clear data to support an enrichment design, prospective pharmacogenetic markerbased hypotheses can still be tested within an unselected design. In this situation, patients are enrolled regard less of pharma cogenetic marker status (although avail ability of an appropriate biologic specimen might be a prerequisite), but the planned analysis incorporates the biomarker as an important component.
One such approach is to include all patients in the trial, but to prespecify multiple hypotheses within the statisti cal design with a careful strategy to limit the overall risk of falsepositive error. If the treatment is thought to be of potential benefit to all patients, but of greater benefit to a specific subpopulation, the RCT might be designed to test the overall population level effect first at a reduced α level from the usual 0.05 (for example test at 0.04). Then, if the overall finding is negative, the remaining α can be used to test for a treatment effect in just the biomarker positive population. An alternative approach is first to use a portion of the α to test for the treatment effect in the biomarkerpositive population then, if the finding is posi tive, to test for activity in the biomarkernegative patients using a prespecified α split. 64 The treatment by pharmacogenetic marker inter active design (Figure 2b ) is a different 'unselected' design approach in which all patients are enrolled, but the pharmacogenetic marker is tested and used as a strati fication factor before patients are randomly assigned to treatment. 65 The trial is then powered to test indepen dently the treatment effect in the two pharmacogenetic markerbased populations. These two groups can be monitored and analysed separately, with independent rules; for example, with aggressive monitoring for futil ity in the patients who do not have the pharmacogenetic marker, if the hypothesis is that the treatment benefit might be reduced or absent (or adverse events increased) in those patients.
When the pharmacogenetic marker is not binary, or when there are multiple pharmacogenetic markers from which to choose for potentially several treatments, the pharmacogeneticmarkerbased strategy design (Figure 2c ) can be used. In this design, patients are ran domly assigned to either their treatment determined by the pharmacogenetic marker or by physician choice or to standard of care. The pharmacogeneticmarkerbased Figure 2 | Some possible prospective biomarker-based clinical trial designs. a | In the enrichment design, patients are tested for the presence of the required biomarker, and only those who have the marker present are randomly assigned to treatment. b | In the treatment by pharmacogenetic maker interaction design, all patients are tested for the biomarker, but then all patients (stratified by marker status) are randomly assigned one of the same two treatment arms to allow determination of the value of the investigational treatment separately in the different biomarker based groups. c | In the marker-based strategy design, patients are randomly assigned to either have treatment defined by their biomarker status, or by a non-marker-based method, such as physician choice. d | In the umbrella trial design, all enrolled patients are assigned to a substudy on the basis of information about multiple biomarkers, and are then randomly assigned to either experimental therapy or standard-of-care treatment. Experimental therapy will differ, and standard-of-care treatment might differ, by substudy. Abbreviation: RCT, randomized clinical trial.
strategy design is inefficient if only one biomarker and treatment is being tested, but continues to be used in trials such as SHIVA, 66 an attempt to validate a genomicguided treatment strategy in metastatic cancer.
Adaptive designs
The use of 'adaptive' designs, which use the data accumu lated during the course of a trial to change study features such as treatment groups, randomization ratio, or end points, has generated much attention among investiga tors designing biomarkerbased RCTs. An example of a cardiovascular RCT incorporating an adaptive design is the GENETICAF trial. 62 Several approaches have been proposed to identify a predictive biomarker within the population used to test a new therapy, if the primary complete population test is negative. This strategy is possible only if the type I error (α) has been partitioned, with some α reserved for the subgroup identification. All such approaches have been criticized as having an over reliance on the data from a single trial both to identify and to validate a biomarker, as well as for the lack of a biologi cal, knowledgedriven algorithm. Other types of adapta tion have been proposed and used in biomarkerbased trials, such as in BATTLE 67 and ISPY2. 68 In these studies, patients were randomly assigned to multiple poten tial treatments, and activity of each treatment assessed within several predefined biomarkerbased groups on an ongoing basis. Substantial controversy exists in the use of adaptive randomization within these trials, where the ratio of patient randomization between the treatment groups is altered to increase the number of patients being treated with agents that are showing the mostpromising early efficacy. A vigorous debate exists about whether such adaptive randomization is desirable from either a statistical or ethical perspective. 69 Biomarker-based all-comers designs A biomarkerbased RCT strategy that has garnered increasing attention over the past 2-3 years is the umbrella trial design (Figure 2d ). In this design, all enrolled patients have their pharmacogenetic marker status tested and are then, on the basis of their pharmacogenetic marker status, assigned to a substudy in which they are randomly allo cated to a specific treatment protocol. Assignment can be to a single treatment, as is planned in the NCI Match trial, 70 with the goal of generating a signal for future trials, or via randomization, which is occurring in the phase II/III LUNGMap study. 70 Hybrid approaches of all of these designs are also possible, for example within the ALCHEMIST trial 70 in adjuvant nonsmall cell lung cancer, in which all patients are screened, and those with specific mutations (ALK or EGFR) are assigned to an RCT, whereas the remain ing patients are genomically profiled and followed up for disease outcomes and survival, but are treated off protocol.
Application in cardiovascular diseases
Despite convincing altered pharmacokinetic and pharma codynamic drug profiles with genetic variation, the clinical implementation of pharmacogenetics in cardiovascular disease has been limited by the lack of demonstration of incremental benefit with the use of pharmacogenetic markers in welldesigned and ade quately powered RCTs. Over the past 6 years, however, the landscape in cardiovascular pharmacogenetics has changed with the initiation of welldesigned RCTs using genotyping strategies to individualize antiplate let, βblocker, statin, and warfarin therapy (Table 1) . Prospective RCTs to assess the use of a pharmaco genetic biomarker to guide prescription of an alternative to standard therapy are underway for βblocker (bucindolol instead of metoprolol) and antiplatelet (ticagrelor instead of clopidogrel) therapy. Clinical outcomes in each of these trials are being directly compared in the carriers of the pharmacogenetic markers. By contrast, alternative dosing strategies for one drug were evaluated in RCTs to assess the use of the pharmacogenetic markers for warfarin sen sitivity, and outcomes were compared for the genotyping versus the nongenotyping groups, rather than by directly assessing the effect of dosing strategy in carriers of the minor allele of the pharmacogenetic markers.
β-Blockers
The use of βblockers (such as bisoprolol, carvedilol, and metoprolol succinate) has resulted in a significant reduc tion in mortality and hospitalizations, and improvement in functional capacity and cardiac structure and func tion in patients with heart failure. [71] [72] [73] However, one βblocker tested in an RCT did not show a significant survival benefit compared with placebo-in the BEST, 74 bucindolol and placebo were associated with 30% and 33% mortality, respectively, in patients with NYHA class III-IV heart failure (P = 0.13). Genetic variation might have a role in the variable clinical response observed with βblocker therapy. The nonsynonymous SNP Arg389Gly, in the gene encoding the β 1 adrenergic receptor ADBR1, is present in 30% of European and Chinese individuals and 40% of individuals with AfricanAmerican ances try. 75 This SNP has differential effects on the function of the β 1 adrenergic receptor in vitro, resulting in a greater reduction in norepinephrine stimulated cAMP produc tion with bucindolol in Arg389transfected cells, com pared with Gly389transfected cells. 16 The increased in vitro βblocker efficacy of bucindolol observed in the β 1 Arg389 genotype translated into a 38% reduction in mortality in β 1 Arg389 carriers treated with bucin dolol compared with placebo in BEST. 16 The β 1 Gly389 c arriers had no survival benefit with bucindolol therapy, raising the possibility that the overall negative results of BEST were caused by an altered drug response owing to underlying genetic variation. This concept is now being tested in GENETICAF. 62 The underlying hypothesis of GENETICAF is that bucindolol used in carriers of the β 1 Arg389 allele is superior to metoprolol therapy in the prevention of the recurrence of symptomatic atrial fibrillation or flutter in patients with heart failure. 62 This doubleblind, genotypedirected RCT incorporates an interim analysis and adaptive design element. If the Data and Safety Monitoring Board determines that phase IIb data for the initial 200 randomly allocated patients is favourable, the trial will proceed to the random assign ment of a total of 620 patients in the phase III component of the RCT. GENETICAF is an example of a prospec tive, pharmacogenetic trial based on the retrospective dis covery of a candidate pharmacodynamic based genetic marker of drug response in a negative phase III RCT, with the new trial enriched for 'genetic responders' .
Statins
Genetic variation in SLCO1B1, a gene that encodes a trans port protein that facilitates the hepatic uptake of statins, has been associated with skeletal myopathy (OR 4.5 in heterozygotes and 16.9 in homozygotes) with simvastatin use. 17 Retrospective DNA analysis was performed in two separate RCTs, in patients with statininduced skeletal myopathy and in controls, to demonstrate this signifi cant association. 17 The genetic variant results in altered SLCO1B1 transporter function, 76 leading to decreased clearance of simvastatin and increased simvastatin plasma levels. 77 These data have led to a recommendation of using a lower dose of simvastatin or considering alternative statins, such as pravastatin or rosuvastatin, in carriers of the SLCO1B1 minor allele. 78 A genetic substudy of JUPITER, in which investigators evaluated the effect of SLCO1B1 variants on clinically reported myalgia in individuals receiving rosuvastatin, did not demonstrate an increased risk attributable to the SLCO1B1 variants. 79 The data for an association between SLCO1B1 genetic variants and myopathy with other statins are either not available or are inconclusive, primarily owing to these studies being underpowered. 78, 80, 81 Clinical implementa tion of simvastatin pharmacogenetics has remained chal lenging, owing to the wide therapeutic index of statins, availability of lowcost alternative statins, and the chal lenge of accurately defining the phenotype of myalgia in clinical practice. In an attempt to make statin pharmaco genetics more relevant to clinical practice, investigators in the Genetically Guided Statin Therapy to Improve Medication Adherence RCT 82 are randomly assigning 375 patients, who have perceived statin intolerance without previous biochemical evidence of severe myopathy, to a Abbreviations: ACS, acute coronary syndromes; AF, atrial fibrillation; CAD, coronary artery disease; INR, international normalized ratio; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
genetically guided statin therapy group or to usual care. The trial is designed to test the hypothesis that genetically guided statin therapy will result in greater statin adher ence and lower LDLcholesterol levels when compared with a nongenotypeguided usual care strategy.
Warfarin
The wide individual variability in warfarin dosing, with its narrow therapeutic index, results in warfarin being the cause of onethird of emergency room visits for adverse drug reactions. 83 Consequently, pharmaco geneticbased warfarin dosing has been extensively studied, and the FDA has included dosing recommendations for war farin in the drug labelling information to reduce dose variability and minimize adverse effects of thrombosis or bleeding. This dosing information is based on genetic variation in CYP2C9, the cytochrome P450 enzyme that metabolizes Swarfarin, and VKORC1, which encodes the enzyme target of warfarin.
No adequately powered RCTs have been performed to assess whether dosing algorithms incorporating phar macogenetics are associated with fewer adverse clinical end points than usual consideration of clinical variables. EUPACT 12 and COAG 13 were designed to examine the role of pharmacogenetics in maintaining patients within a therapeutic international normalized ratio (INR) range (2-3) and were both completed in 2013.
EUPACT 12 was an RCT involving 455 patients. One trial group received standard dosing (individuals aged ≤75 years received 10 mg on day 1, and 5 mg on days 2 and 3, whereas patients aged >75 years received 5 mg daily on days 1-3), and the other group received genotypeguided dosing. The primary outcome-the percentage of time that the trial participants were in therapeutic INR over a 12week period-was 67.4% in the genotyping group and 60.3% in the standarddosing group (P <0.001). 12 Fewer patients in the genotyping group compared with the standarddosing group had an INR >4 (27% versus 37%; P = 0.03). The median time to achieving therapeutic INR was also shorter in the genotyping group than in patients receiving the standard dosing (21 days versus 29 days; P <0.001). Therefore, the EUPACT trial 12 indicated that a pharmacogeneticbased dosing strategy might be more desirable than conventional warfarin dosing. COAG 13 was a doubleblind RCT to assess the percent age of time in therapeutic INR over a 4week period in patients who received either genotypingguided dosing or dosing guided on the basis of clinical variables only. The primary outcome did not vary between the two groupsthe percentage of time in therapeutic INR was 45.4% in the standarddosing group and 45.2% in the geno typingguided group (P = 0.91). 13 However, in African American individuals, who comprised onethird the study population, clinicalvariable dosing was found to be superior to genotypingbased dosing (P = 0.01). Notably, though, 76% of AfricanAmerican participants had no genetic variation in the two genes assessed (compared with 25% of nonAfricanAmerican participants). Genetic variants that help to predict warfarin dosing variability in AfricanAmerican individuals-such as CYP2C9*5, *6, *8, and *11-were not tested for and, therefore, were not used to guide dosing in the COAG trial. 13 Important differences between the EUPACT 12 and COAG 13 trials exist. The control group in the EUPACT trial 12 received fixed dosing, whereas the control group in the COAG trial 13 used clinical variables such as age, sex, AfricanAmerican ethnicity, and concomitant drug use to determine dose. One might predict the clinical variable dosing strategy to be more precise than fixed dosing; however, at 4 weeks, the percentage of time spent in therapeutic INR was equivalent with fixed dosing in EUPACT 12 and with clinicalvariable dosing in COAG. 13 Another important difference was that genotyping results were made available within 2 h for individuals in the EUPACT trial, but took longer in the COAG trial. All day 1 dosing was determined on the basis of genotype in the genotyping group of EUPACT. 12 By contrast, in the COAG trial, 13 only 45% of participants had genetic infor mation available to guide dosing on day 1, although 99% of participants had genetic information to guide dosing by day 3. Furthermore, AfricanAmerican patients comprised almost onethird of the study population in the COAG trial, 13 but only 1% of the p opulation of EUPACT 12 were black patients. The presence of AfricanAmerican indi viduals who had results opposite to the predicted effects of genotyping might have resulted in a negative outcome in the COAG study. 13 Finally, when comparing a genotype based strategy with a nongenotypebased strategy, it is important to assess the prevalence of the genetic variants in the two groups and to ensure sample size calculations are made on the basis of the effect of the genetic vari ants on the phenotype as well as the prevalence of these variants. In the geno typing group, the prevalence of indi viduals homo zygous for VKORC1 was 11% in the COAG trial, 13 but was 17% in the EUPACT trial. 12 Similarly, only 1% of study parti cipants in the COAG study 13 were homozygous CYP2C9 carriers, compared with 3.4% of individuals in the EUPACT trial. 12 According to FDA recommendations, warfarin dosing is typically 5-7 mg per day in individuals who do not carry these genetic vari ants, whereas patients who are homozygous for VKORC1 and CYP2C9*2 should be receiving doses that are almost 40% lower (3-4 mg per day), and warfarin dosing is even further reduced for carriers of the CYP2C9*3 allele (recommended to be 0.5-2 mg per day). 84 Whether trial results would have been different if a greater proportion of participants with warfarin sensitivity had been identified by genotype remains unknown, especially for the COAG trial. The most important question-whether pharmaco genetic testing affects clinical outcomes such as thrombo embolic or bleeding events-remains to be assessed, and in the absence of demonstrating such benefit, insurance reimbursement for pharmacogenetic testing for warfarin remains problematic.
Clopidogrel
Clopidogrel is the drug most commonly prescribed with aspirin after PCI, with >2 million prescriptions written in the USA each month. 85 Clopidogrel is a thienopyri dine prodrug that requires the cytochrome P450 enzyme CYP2C19 to convert it to its active thiol metabolite. Common genetic variation in CYP2C19 (*2 and *3 alleles) leads to a loss ofunctional protein. This variation occurs in approximately 30% of the white population and 50% of Asian individuals. [86] [87] [88] Carriers of CYP2C19*2 and *3 alleles (or lossoffunction alleles) have significantly reduced clopidogrel active metabolite levels and high residual platelet reactivity. Preliminary data suggest that, when treated with clopidogrel, these carriers might be at an increased risk of major adverse cardiovascular events, especially after PCI, compared with noncarriers. 35, 36, [89] [90] [91] As a result, the FDA have issued a black box warning advising practitioners to "consider alternative treatment in patients identified as CYP2C19 poor metabolizers" and note that these patients can be identified by geno typing. 92 However, routine clinical use of genotyping to identify CYP2C19 lossoffunction alleles in patients treated with clopidogrel is not recommended in the latest guidelines published by the American College of Cardiology, American Heart Association, and Society for Cardiovascular Angiography and Interventions, 93, 94 owing to the lack of prospective clinical evidence that such patients with CYP2C19 lossoffunction alleles would benefit from alternative therapy.
To address this gap in clinical evidence, a large, pro spective RCT of genotypedirected antiplatelet therapy compared with routine care is underway. TAILORPCI 61 will help to determine whether prospectively identifying patients with CYP2C19 lossoffunction alleles, and pre scribing these individuals alternative antiplatelet therapy (such as ticagrelor), would be clinically beneficial. A total of 5,270 patients with stable coronary artery disease or acute coronary syndromes who have undergone PCI will be enrolled to either routine care or prospective CYP2C19 genotyping using a 'pointofcare' FDAapproved geno typing platform. The primary analysis will be con ducted only in the approximately 1,694 atrisk patients with CYP2C19*2 or *3 alleles who have either received clopidogrel (in the control group) or ticagrelor (in the genotype group). The primary end points of the trial include myocardial infarction, stroke, cardiovascular death, severe recurrent ischaemia, and stent thrombosis at 1 year. A secondary aim is to assess the incidence of major or minor bleeding in participants with CYP2C19 lossoffunction allele(s) receiving ticagrelor versus those receiving clopidogrel.
In contrast to TAILORPCI, a superiority trial in which investigators are prospectively comparing the use of ticagrelor with clopidogrel in CYP2C19 lossof function carriers, the POPular Genetics study 14, 95 is a non inferiority trial, in which a genotyping strategy (ticagrelor in CYP2C19 lossoffunction allele carriers and clopi dogrel in wildtype patients) is being compared with the universal use of ticagrelor or prasugrel in the nongeno typing group. The POPular Genetics study investigators plan to enrol 2,700 individuals who have undergone primary PCI after a STsegment elevation myocardial infarction; patients who have received thrombo lytics will be excluded. The primary end point is a net clinical benefit end point, and consists of a composite of death, stroke, myocardial infarction, stent thrombosis, urgent revascularization, and major bleeding at 1 year.
Both these trials are designed to determine whether patients preemptively identified by genotyping as being clopidogrel resistant have improved clinical outcomes after PCI if they are treated with alternative therapy, such as ticagrelor or prasugrel. These trials will also hopefully inform us on whether selective use of prasugrel or ticagre lor in carriers of the CYP2C19 lossoffunction allele can minimize the bleeding risks that are usually associated with these newer P2Y 12 inhibitors, especially in those who could potentially benefit most from the drug. If so, this strategy could lead to a reduction in overall costs.
Challenges and future directions
Although RCTs are considered the gold standard of medical science, whether RCTs are the best modality to enable clinical implementation of pharmacogenet ics is controversial. 96 For example, conducting RCTs to assess the clinical utility of testing for rare genetic vari ants with large effect sizes that help to predict rare, but life threatening, adverse drug reactions is impractical. Various legal and ethical considerations to performing genotypebased RCTs also exist. 97 Detection of adverse drug reactions in a genotypically homogeneous and small study population might be difficult, and this lack of detec tion could pose unique risks, especially when prescribing a drug for 'offlabel' use. Furthermore, if genetic testing identifies drug 'nonresponders' , these individuals might be viewed as economically burdensome to the healthcare system, which might raise privacy concerns and stigmati zation fears for the patient. Drugs prescribed on the basis of genotype might also suffer the same fate as orphan drugs, resulting in higher costs to patients and thirdparty payers. The increased costs might stem from the need for a financial incentive for pharmaceutical companies to want to participate in this type of research, given the substantial cost of RCTs and the potential to benefit only a select group of patients.
To reduce costs, pharmacogenetic studies designed to demonstrate clinical utility are becoming increasingly pragmatic. For example, genetic association studies have been performed using electronic health records linked to DNA biobanks. 98 Warfarin doses have been electronically extracted and pharmacogenetic studies have successfully replicated the association between stable warfarin dosing and genetic variants in VKORC1 and CYP2C9. 99 The utility of pharmacogenetic information pre emptively made available in the electronic health record, with clini cal decision support modules, is being assessed in the eMERGEPGx project. 100 In this study, 9,000 patients will undergo nextgeneration sequencing to assess vari ation in 84 genes related to commonly prescribed drugs, and the genetic information will be integrated into the electronic health record. Information about a clinically validated pharmacogenetic marker will automatically be made available to the physician electronically, with a deci sion support module, when the corresponding drug is being prescribed. Physician prescribing patterns and clin ical outcomes will be tracked. Whether such pragmatic approaches using electronic health records will enable clinical implementation of pharmacogenetics and will preclude the need for genotypebased RCTs remains to be seen.
Conclusions
Although costs of DNA genotyping and sequencing have dramatically decreased over the past decade, the identifi cation and clinical implementation of pharmacogenetic markers remains a challenge. The easy availability of DNA samples from adequately powered, wellconducted clinical trials for both discovery and replication of pharma cogenetic markers is limited. Defining an accu rate drugresponse phenotype is also difficult, because clinical end points are often heterogeneous and not directly related to drug effect. Currently used techniques, such as GWAS, have been unable to identify genetic vari ants significantly associated with drugresponse pheno types in >50% of analysed cases. 101 The negative results of these studies have been attributed to 'missing herit ability' of complex traits, and might be a consequence of the presence of rare variants. 26 Nextgeneration sequencing allows identification of these rare variants, but the expense of performing whole exome or whole genome sequencing in large studies, the statistical chal lenges of associating rare variants with drugresponse phenotypes, and the limited accuracy of these techniques in detecting certain types of genetic variants, limit their use in pharmacogenomics. 4 Although knowledge of rare variants might enable insight into drug biology, the use of these variants as a pharmacogenetic marker might not be practical. Despite successful identifica tion of several pharmacogenetic markers, the functional annotation of these variants-such as the combined effect of gainof function and lossoffunction genetic variants on the drug phenotype-is unknown and, in the context of multiple drugs that have interactions with each other, the effect of pharmacogenetic variation on overall drug pheno type is also unknown. 102 Ensuring the validity of the pharmacogenetic marker is, therefore, critically important before implementation of the marker into clinical practice. Adequately powered, pragmatic, prospective RCTs are required to translate the use of pharmacogenetic markers into clinical practice.
